ECSP19047259A - Combinación farmacéutica para el tratamiento del dolor - Google Patents

Combinación farmacéutica para el tratamiento del dolor

Info

Publication number
ECSP19047259A
ECSP19047259A ECSENADI201947259A ECDI201947259A ECSP19047259A EC SP19047259 A ECSP19047259 A EC SP19047259A EC SENADI201947259 A ECSENADI201947259 A EC SENADI201947259A EC DI201947259 A ECDI201947259 A EC DI201947259A EC SP19047259 A ECSP19047259 A EC SP19047259A
Authority
EC
Ecuador
Prior art keywords
pain
components
treatment
combination
administered
Prior art date
Application number
ECSENADI201947259A
Other languages
English (en)
Inventor
Petra Bloms-Funke
Klaus Schiene
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42395008&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP19047259(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of ECSP19047259A publication Critical patent/ECSP19047259A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una combinación que comprende a modo de componentes, (a) por lo menos un compuesto 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol, y (b) por lo menos un antagonista de NMDA, una formulación farmacéutica y una forma de dosificación que comprende dicha combinación, así como un método de tratamiento del dolor, por ejemplo dolor inflamatorio o dolor neuropático, en la que los componentes (a) y (b) se administran simultáneamente o secuencialmente en un mamífero, de manera que el componente (a) puede administrarse antes o después del componente (b) y de manera que los componentes (a) o (b) se administran en el mamífero mediante la misma vía de administración o vías diferentes.
ECSENADI201947259A 2010-06-15 2019-07-02 Combinación farmacéutica para el tratamiento del dolor ECSP19047259A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10006202 2010-06-15

Publications (1)

Publication Number Publication Date
ECSP19047259A true ECSP19047259A (es) 2019-07-31

Family

ID=42395008

Family Applications (2)

Application Number Title Priority Date Filing Date
ECSP12012217 ECSP12012217A (es) 2010-06-15 2012-10-03 Combinación Farmaceutica para el tratamiento del dolor
ECSENADI201947259A ECSP19047259A (es) 2010-06-15 2019-07-02 Combinación farmacéutica para el tratamiento del dolor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ECSP12012217 ECSP12012217A (es) 2010-06-15 2012-10-03 Combinación Farmaceutica para el tratamiento del dolor

Country Status (29)

Country Link
US (3) US8846765B2 (es)
EP (2) EP2992877A1 (es)
JP (3) JP6133772B2 (es)
KR (1) KR101831616B1 (es)
CN (1) CN103108631B (es)
AR (1) AR081931A1 (es)
AU (2) AU2011267474B2 (es)
BR (1) BR112012031836A2 (es)
CA (1) CA2796774C (es)
CL (1) CL2012002551A1 (es)
CO (1) CO6602157A2 (es)
CY (1) CY1117118T1 (es)
DK (1) DK2582366T3 (es)
EC (2) ECSP12012217A (es)
ES (1) ES2560676T3 (es)
HK (1) HK1215787A1 (es)
HR (1) HRP20151327T1 (es)
HU (1) HUE026619T2 (es)
IL (1) IL221926A (es)
MX (1) MX2012014482A (es)
NZ (1) NZ602625A (es)
PE (2) PE20130243A1 (es)
PL (1) PL2582366T3 (es)
PT (1) PT2582366E (es)
RS (1) RS54439B1 (es)
RU (2) RU2589692C2 (es)
SI (1) SI2582366T1 (es)
WO (1) WO2011157391A1 (es)
ZA (1) ZA201208646B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6133772B2 (ja) 2010-06-15 2017-05-24 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 痛み治療用の医薬配合物
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
WO2013138322A1 (en) * 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
RS59687B1 (sr) 2013-01-22 2020-01-31 Vistagen Therapeutics Inc Oblici doziranja i terapeutske primene l-4-hlorkinurenina
AU2014240102A1 (en) 2013-03-15 2015-09-17 Janssen Pharmaceutica Nv Pharmaceutical composition of S-ketamine hydrochloride
CN103655523A (zh) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 他喷他多组合物
MX2016014581A (es) * 2014-05-06 2018-02-16 Univ Northwestern Composiciones de compuestos que modulan nmdar.
CA2957926A1 (en) 2014-08-13 2016-02-18 Janssen Pharmaceutica Nv Method for the treatment of depression
AU2015318123A1 (en) 2014-09-15 2017-03-30 Janssen Pharmaceutica Nv Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
CN107847469A (zh) 2015-06-27 2018-03-27 美国神农制药责任有限公司 氯胺酮透皮递送系统
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
IL319020A (en) 2017-12-22 2025-04-01 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
WO2019200345A1 (en) 2018-04-12 2019-10-17 Anavex Life Sciences Corp. A2-73 crystalline polymorph compositions of matter and methods of use thereof
WO2020178653A1 (en) 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6248789B1 (en) * 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6007841A (en) * 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
WO2000003716A1 (en) 1998-07-16 2000-01-27 Memorial Sloan-Kettering Cancer Center Topical compositions comprising an opioid analgesic and an nmda antagonist
DE10005302A1 (de) * 2000-02-07 2002-01-17 Gruenenthal Gmbh Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
DE10163421A1 (de) * 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
JP2003201254A (ja) * 2001-12-28 2003-07-18 Hisamitsu Pharmaceut Co Inc 鎮痛剤活性増強剤の治療上有効な血中濃度を維持するための製剤
JP2003210254A (ja) * 2002-01-18 2003-07-29 Nihon Form Service Co Ltd 車椅子専用ラック
US20060240128A1 (en) 2002-09-09 2006-10-26 Schlagheck Thomas G Combined immediate release and extended release analgesic composition
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US20090082466A1 (en) * 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
PL2012763T3 (pl) 2006-04-28 2011-08-31 Gruenenthal Gmbh Kombinacja farmaceutyczna zawierająca 3-(3-dimetyloamino-1-etylo-2-metylo-propylo)-fenol i NSAID
WO2007128413A1 (en) 2006-04-28 2007-11-15 Grünenthal GmbH Pharmaceutical combination comprising 3- ( 3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and paracetamol
US20070254960A1 (en) 2006-04-28 2007-11-01 Gruenenthal Gmbh Pharmaceutical combination
EP1857463A1 (en) 2006-05-03 2007-11-21 Ebewe Pharma Ges.m.b.H. Nfg. KG Peptide having neuroprotective effects
WO2007141018A1 (en) 2006-06-08 2007-12-13 Schwarz Pharma Ag Therapeutic combination for painful medical conditions
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007012165A1 (de) * 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
CN102065852B (zh) * 2007-11-23 2015-06-17 格吕伦塔尔有限公司 他喷他多组合物
US7872046B2 (en) * 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
HUE043278T2 (hu) * 2008-09-05 2019-08-28 Gruenenthal Gmbh 3-(3-dimetilamino-1-etil-2-metil-propil)-fenolt és pregabalint vagy gabapentint tartalmazó gyógyszerkombináció
JP6133772B2 (ja) 2010-06-15 2017-05-24 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 痛み治療用の医薬配合物
MX2013003354A (es) 2010-09-21 2013-06-24 Purdue Pharma Lp Analogos de buprenorfina.
CA2991216C (en) 2010-12-22 2020-04-28 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
EA024193B1 (ru) 2011-03-04 2016-08-31 Грюненталь Гмбх Фармацевтическая композиция на водной основе, предназначенная для парентерального введения тапентадола
MX2014011855A (es) 2012-04-17 2016-09-09 Purdue Pharma Lp Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides.

Also Published As

Publication number Publication date
KR20130111945A (ko) 2013-10-11
HRP20151327T1 (hr) 2016-01-01
ECSP12012217A (es) 2012-11-30
JP2017141277A (ja) 2017-08-17
JP6133772B2 (ja) 2017-05-24
PL2582366T3 (pl) 2016-04-29
CN103108631A (zh) 2013-05-15
CO6602157A2 (es) 2013-01-18
AU2016219643A1 (en) 2016-09-15
RU2589692C2 (ru) 2016-07-10
MX2012014482A (es) 2013-02-21
CY1117118T1 (el) 2017-04-05
US20110306674A1 (en) 2011-12-15
WO2011157391A1 (en) 2011-12-22
EP2582366B1 (en) 2015-10-28
RU2016119041A (ru) 2017-11-20
AU2016219643B2 (en) 2018-04-12
AU2011267474A1 (en) 2013-01-10
JP6423036B2 (ja) 2018-11-14
US20170333369A1 (en) 2017-11-23
US20140309311A1 (en) 2014-10-16
HK1184370A1 (zh) 2014-01-24
CL2012002551A1 (es) 2012-11-09
IL221926A (en) 2015-08-31
RU2013101515A (ru) 2014-07-20
EP2992877A1 (en) 2016-03-09
HUE026619T2 (en) 2016-06-28
PE20160531A1 (es) 2016-06-05
SI2582366T1 (sl) 2016-02-29
JP6197007B2 (ja) 2017-09-13
CN103108631B (zh) 2015-08-26
RS54439B1 (sr) 2016-06-30
EP2582366A1 (en) 2013-04-24
AR081931A1 (es) 2012-10-31
US8846765B2 (en) 2014-09-30
AU2011267474B2 (en) 2016-05-26
KR101831616B1 (ko) 2018-04-04
NZ602625A (en) 2014-03-28
JP2013528629A (ja) 2013-07-11
PT2582366E (pt) 2016-01-26
JP2015232015A (ja) 2015-12-24
BR112012031836A2 (pt) 2016-11-08
RU2675261C2 (ru) 2018-12-18
CA2796774A1 (en) 2011-12-22
HK1215787A1 (en) 2016-09-15
CA2796774C (en) 2020-06-02
ES2560676T3 (es) 2016-02-22
ZA201208646B (en) 2013-09-25
DK2582366T3 (en) 2015-12-07
PE20130243A1 (es) 2013-03-22
US10813890B2 (en) 2020-10-27

Similar Documents

Publication Publication Date Title
ECSP19047259A (es) Combinación farmacéutica para el tratamiento del dolor
AR117613A2 (es) Combinación farmacéutica
CR20150326A (es) Inhibidores de autotaxina
UY32925A (es) Composiciones de corticosteroides de administración oral
MX2015002378A (es) Composicion ansiolitica, formulacion y metodo de uso.
ECSP17013617A (es) “combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y nsaid”
CU20140068A7 (es) Triazolopiridinas sustituidas
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
MX360024B (es) Composicion para el tratamiento de la hiperlipidemia que comprende un derivado de oxintomodulina.
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
CO6710926A2 (es) Compuestos de n-heteroarilo
UY32819A (es) Composiciones farmaceuticas de uso oftalmico de antagonistas del receptor dp2
CL2013003527A1 (es) Compuestos heterociclicos antagonistas de los receptores muscarinicos y agonistas del receptor beta2 adrenergico; su composicion farmaceutica; su combinacion; un dispositivo y su uso en la prevencion y/o el tratamiento de enfermedades bronco-obstructivas o inflamatorias como asma y epoc.
MX2013015274A (es) Anatagonista trpm8 y su uso en tratamientos.
CU20120171A7 (es) Triazolopiridinas sustituidas
CR20130569A (es) Análogos del ácido epoxieicosatrienoicos y métodos de toma y uso del mismo
MX2017004440A (es) Una formulacion de rapamicina inhalable para el tratamiento de hipertension pulmonar.
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
DOP2016000007A (es) Pirazolpiridinas sustituidas
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
MX390384B (es) Formulaciones farmaceuticas para liberacion sostenida de ester de sebacoil dinalbufina.
ECSP11010876A (es) Combinación farmacéutica que contiene el 6-dimetilaminometil-1-(3-metoxi-fenil)-ciclohexano-1,3-diol y paracetamol
MX376160B (es) Compuestos que tienen actividad antagonista del receptor muscarínico y actividad agonista del receptor beta2 adrenérgico.